Serological Remission Defined by Anti-Integrin αvβ6 Antibody Predicts Long-Term Clinical Remission of Ulcerative Colitis.

Fifty-three of 149 patients experienced relapse.

The 1-year, 2-year, and 3-year cumulative relapse rates were 12.1%, 22.2%, and 32.9%, respectively.

V6 antibody levels were significantly higher in patients who relapsed.

Cumulative 1-year, 2-year, and 3-year relapse rates were 0.0%, 0.0%, and 8.8%, respectively, in patients with ≤4.23U/mL.